Holen Sie sich die Stockscreener-App
71.94
0.76%
0.505
Handel nachbörslich:
72.57
0.625
+0.87%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt DXCM?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$71.44
Offen:
$71.5
24-Stunden-Volumen:
7.44M
Relative Volume:
1.51
Marktkapitalisierung:
$27.74B
Einnahmen:
$4.82B
Nettoeinkommen (Verlust:
$930.40M
KGV:
30.77
EPS:
2.3381
Netto-Cashflow:
$1.43B
1W Leistung:
+24.49%
1M Leistung:
+14.98%
6M Leistung:
+19.51%
1J Leistung:
-15.21%
1-Tages-Spanne:
$70.18
$72.27
1-Wochen-Bereich:
$59.46
$72.27
52-Wochen-Spanne:
$54.11
$89.98
Dexcom Inc Stock (DXCM) Company Profile
Firmenname
Dexcom Inc
Sektor
Branche
Telefon
(858) 200-0200
Adresse
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Compare DXCM vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
71.89 | 27.57B | 4.82B | 930.40M | 1.43B | 2.3381 |
ABT
Abbott Laboratories
|
87.76 | 153.94B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
313.46 | 123.25B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
78.14 | 100.34B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
57.13 | 84.23B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
83.20 | 47.77B | 6.30B | 1.07B | 1.09B | 1.8406 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-24 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2026-01-12 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2025-12-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-25 | Eingeleitet | Evercore ISI | In-line |
| 2025-10-21 | Fortgesetzt | Stifel | Buy |
| 2025-09-08 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-08-21 | Eingeleitet | Argus | Buy |
| 2025-06-16 | Eingeleitet | Truist | Buy |
| 2025-05-30 | Eingeleitet | Goldman | Buy |
| 2025-04-10 | Eingeleitet | Mizuho | Outperform |
| 2025-02-03 | Hochstufung | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-07-26 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | Eingeleitet | Redburn Atlantic | Neutral |
| 2024-03-12 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-04-17 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | Eingeleitet | UBS | Buy |
| 2023-01-26 | Eingeleitet | Wolfe Research | Outperform |
| 2022-10-18 | Eingeleitet | Barclays | Equal Weight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-07-15 | Eingeleitet | Bernstein | Outperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-02-03 | Hochstufung | BTIG Research | Neutral → Buy |
| 2022-01-19 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-10-18 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-07-21 | Fortgesetzt | Cowen | Outperform |
| 2021-05-28 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Overweight |
| 2021-01-06 | Hochstufung | UBS | Neutral → Buy |
| 2020-10-02 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | Bestätigt | Piper Sandler | Overweight |
| 2020-05-14 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2019-11-07 | Bestätigt | Canaccord Genuity | Buy |
| 2019-11-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-10-23 | Eingeleitet | Stifel | Buy |
| 2018-11-28 | Eingeleitet | UBS | Neutral |
| 2018-10-19 | Hochstufung | Goldman | Sell → Neutral |
| 2018-09-12 | Hochstufung | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | Bestätigt | Canaccord Genuity | Buy |
| 2018-07-02 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-05-11 | Eingeleitet | BofA/Merrill | Buy |
| 2018-05-03 | Bestätigt | Canaccord Genuity | Buy |
| 2018-04-04 | Eingeleitet | Goldman | Sell |
| 2018-04-04 | Eingeleitet | Guggenheim | Neutral |
| 2018-03-23 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | Herabstufung | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | Bestätigt | Wedbush | Outperform |
Alle ansehen
Dexcom Inc Aktie (DXCM) Neueste Nachrichten
DexCom Inc. stock outperforms competitors on strong trading day - MarketWatch
Dexcom stock (US2521311074): Insider sale adds focus on shares - AD HOC NEWS
The DexCom Stock Turnaround Is Showing Real Signs of Life - Barchart.com
DexCom Inc. stock underperforms Friday when compared to competitors - MSN
Dexcom stock (US2521311074): Insider sale and sharp price jump put CGM specialist in focus - AD HOC NEWS
DXCM to Launch Dexcom Flex CGM System for Type 2 Diabetes in Germany - Zacks Investment Research
Elliott strikes Dexcom board settlement after taking stake - MSN
Devon Energy Corp stock (US2521311074): earnings momentum and oil price tailwinds in focus - AD HOC NEWS
A Look at DexCom Inc (DXCM) After 5.6% Gain -- GF Value $102.05 vs Price $65.09 - GuruFocus
Dexcom Inc. stock (US2521311074): buyback, 2030 targets and activist deal fire up DXCM - AD HOC NEWS
DexCom : Operations and Innovation Committee - marketscreener.com
DexCom, Inc.Common Stock (NQ: DXCM - The Chronicle-Journal
DexCom Is Maintained at Buy by Canaccord Genuity - Moomoo
A Potential Turnaround Stock In Digital Healthcare - Good Money Guide
Here's why you should hold DexCom stock in your portfolio for now - MSN
DexCom (DXCM) Introduces Dexcom Flex for Type 2 Diabetes Patients - GuruFocus
DexCom Price Target Cut to $80.00/Share From $100.00 by B of A Securities - Moomoo
Dexcom stock (US2521311074): Analyst moves follow Elliott deal and new long-term targets - AD HOC NEWS
Redefining CGM for People With Type 2 Diabetes: Dexcom Announces Dexcom Flex in Germany - 01net
Redefining CGM for People With Type 2 Diabetes: Dexcom Announces - GuruFocus
DexCom Stock Jumps As 2030 Targets Ignite Bullish Trading - StocksToTrade
Dexcom Reveals Flex CGM for Type 2 Diabetes Patients - Medical Product Outsourcing
DexCom, Inc. Stock 12‑Month Price Target Cut to $82.28, Implies 34% Upside - TradingView
Wearables in Pharma & Biotech Research and Forecasts Report 2026-2031, Company Profiles and Market Strategies of Abbott, Dexcom, and Masimo - Yahoo Finance
DexCom Expands CGM Access in Germany With New Dexcom Flex System for Type 2 Diabetes - Moomoo
BofA Securities Adjusts Price Target on DexCom to $80 From $100 - marketscreener.com
DexCom Stock Jumps After Diabetes Management Firm Reaches Agreement With Elliott Investment Management - TIKR.com
DexCom, Inc. (DXCM) Stock Analysis: 33.77% Potential Upside Attracts Investor Attention - DirectorsTalk Interviews
Dexcom Inc. stock (US2521311074): diabetes tech player in focus after recent share move - AD HOC NEWS
DexCom Stock Up on Q1 Earnings & Revenues Beat, Margins Rise - MSN
DexCom, Inc. (DXCM) Analyst/Investor DaySlideshow (NASDAQ:DXCM) 2026-05-17 - Seeking Alpha
symbol__ Stock Quote Price and Forecast - CNN
Stephens Investment Management Group LLC Boosts Stock Position in DexCom, Inc. $DXCM - MarketBeat
Assessing DexCom (DXCM) Valuation After Investor Day Targets And New US$1b Buyback Plan - Yahoo Finance
Did New Long-Term Targets and US$1 Billion Buyback Just Shift DexCom's (DXCM) Investment Narrative? - Yahoo Finance
DexCom Maps G8 Launch, Coverage Expansion and Double-Digit Growth at Investor Day - sharewise.com
DexCom Stock Jumps As 2030 Growth Targets And Buybacks Ignite Bullish Momentum - timothysykes.com
DexCom (DXCM) Unveils Ambitious Financial Targets and Share Repu - GuruFocus
Elliott to get two board seats at Dexcom ahead of investor day - MSN
DNB Asset Management AS Boosts Position in DexCom, Inc. $DXCM - MarketBeat
Bank Julius Baer & Co. Ltd Zurich Sells 98,913 Shares of DexCom, Inc. $DXCM - MarketBeat
DexCom (DXCM) Posts Upbeat 2026, Climbs 6.6% - Insider Monkey
DexCom Inc (DXCM) Shares Surge 6.6% -- What GF Score of 88 Tells Investors - GuruFocus
What Does Rep. Khanna's Spouse's DXCM Trade Signal for Diabetes Tech - Kavout
Michael Brown reports two 1,700-share DXCM sales through Morgan Stanley (DXCM) - Stock Titan
DexCom (DXCM) Shares Rise 5.5% Amid Market Decline - GuruFocus
Finanzdaten der Dexcom Inc-Aktie (DXCM)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.19%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):